Stockscreener 앱 받기
6.57
3.24%
-0.22
시장 영업 전:
6.70
0.13
+1.98%
전일 마감가:
$6.79
열려 있는:
$6.84
하루 거래량:
527.08K
Relative Volume:
0.42
시가총액:
$479.53M
수익:
-
순이익/손실:
$-86.60M
주가수익비율:
-2.3196
EPS:
-2.8324
순현금흐름:
$-67.37M
1주 성능:
-4.64%
1개월 성능:
-19.09%
6개월 성능:
+40.69%
1년 성능:
+66.33%
1일 변동 폭
$6.39
$6.93
1주일 범위
$6.39
$7.55
52주 변동 폭
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
6.57 | 495.58M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Raymond James | Strong Buy |
| 2025-11-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 개시 | Guggenheim | Buy |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2024-06-06 | 개시 | H.C. Wainwright | Buy |
| 2023-11-28 | 개시 | Chardan Capital Markets | Buy |
| 2023-11-28 | 개시 | JP Morgan | Overweight |
| 2023-11-28 | 개시 | Leerink Partners | Outperform |
| 2023-11-28 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-28 | 개시 | Stifel | Buy |
모두보기
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Quarterly Risk: Is Lexeo Therapeutics Inc forming a bullish divergence2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Is Lexeo Therapeutics Inc backed by strong institutional buyingPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Lexeo Therapeutics Announces Head of Research Transition - The Globe and Mail
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - 富途牛牛
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program - Yahoo Finance
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program - Finviz
Lexeo TherapeuticsRevolutionizing Heart Health With Gene Therapies - RTTNews
Lexeo Therapeutics Announces Key Executive Leadership Changes - The Globe and Mail
Lexeo Therapeutics Announces Key Leadership Appointments - citybiz
Lexeo Therapeutics appoints new COO and CMO, announces executive transition - Investing.com Nigeria
Lexeo Therapeutics appoints new COO and CMO, announces executive transition By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Executive Appointments - marketscreener.com
Lexeo Therapeutics Announces Key Executive Appointments - TradingView
Lexeo appoints Jose Manuel Otero as COO - TipRanks
Lexeo Therapeutics announces key leadership appointments By Investing.com - Investing.com Nigeria
Lexeo Therapeutics announces key leadership appointments - Investing.com
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - The Manila Times
Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative
New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - stocktitan.net
Investor Mood: Can Lexeo Therapeutics Inc be the next market leaderJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Financial Analysis: Esperion Therapeutics (NASDAQ:ESPR) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Weekly Trades: Whats next for Lexeo Therapeutics Inc stockJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Volume Recap: Is Bassett Furniture Industries Incorporated stock technically oversoldWeekly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Fund Flows: What is GNSRTs debt to equity ratioWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
Market Wrap: Can Lexeo Therapeutics Inc ride the EV waveJuly 2025 Setups & Daily Technical Forecast Reports - baoquankhu1.vn
Technical Analysis: Is Lexeo Therapeutics Inc subject to activist investor interestJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Block Trades: Does Lexeo Therapeutics Inc have a sustainable dividend2025 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Does Lexeo Therapeutics Inc have a sustainable dividendPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright - TipRanks
Aug Update: Is SLAB subject to activist investor interestWeekly Investment Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug Decliners: Will Lexeo Therapeutics Inc outperform its industry peersEarnings Risk Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Price Action: Will Lexeo Therapeutics Inc outperform its industry peersAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
LXEO: Cardiac gene therapy programs show strong efficacy, safety, and commercial readiness - TradingView — Track All Markets
Heart-disease gene therapy race heating up as Lexeo posts data - BioWorld MedTech
Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 6.5%Should You Sell? - MarketBeat
Day Trade: Will Lexeo Therapeutics Inc stock outperform growth indexesJuly 2025 Setups & Safe Entry Point Alerts - Bộ Nội Vụ
H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com Canada
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Aug Intraday: Will Lexeo Therapeutics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Stepwise Trade Signal Guides - Bộ Nội Vụ
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo’s gene therapy shows promising results for heart condition By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Reflects Structural Trends In Clinical Biotech - Kalkine Media
Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap DownHere's What Happened - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 - TradingView — Track All Markets
Lexeo Therapeutics stock falls after PKP2 gene therapy data By Investing.com - Investing.com Canada
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):